GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (XPAR:BIM) » Definitions » EV-to-FCF

BioMerieux (XPAR:BIM) EV-to-FCF : 113.54 (As of Apr. 27, 2024)


View and export this data going back to 2004. Start your Free Trial

What is BioMerieux EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BioMerieux's Enterprise Value is €12,160 Mil. BioMerieux's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €107 Mil. Therefore, BioMerieux's EV-to-FCF for today is 113.54.

The historical rank and industry rank for BioMerieux's EV-to-FCF or its related term are showing as below:

XPAR:BIM' s EV-to-FCF Range Over the Past 10 Years
Min: 17.56   Med: 49.48   Max: 126.25
Current: 111.38

During the past 13 years, the highest EV-to-FCF of BioMerieux was 126.25. The lowest was 17.56. And the median was 49.48.

XPAR:BIM's EV-to-FCF is ranked worse than
86.41% of 103 companies
in the Medical Diagnostics & Research industry
Industry Median: 24.94 vs XPAR:BIM: 111.38

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-27), BioMerieux's stock price is €101.50. BioMerieux's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €3.010. Therefore, BioMerieux's PE Ratio for today is 33.72.


BioMerieux EV-to-FCF Historical Data

The historical data trend for BioMerieux's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMerieux EV-to-FCF Chart

BioMerieux Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 72.05 45.13 27.09 61.26 112.54

BioMerieux Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.09 - 61.26 - 112.54

Competitive Comparison of BioMerieux's EV-to-FCF

For the Diagnostics & Research subindustry, BioMerieux's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioMerieux's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BioMerieux's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where BioMerieux's EV-to-FCF falls into.



BioMerieux EV-to-FCF Calculation

BioMerieux's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=12159.730/107.1
=113.54

BioMerieux's current Enterprise Value is €12,160 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioMerieux's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €107 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioMerieux  (XPAR:BIM) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

BioMerieux's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=101.50/3.010
=33.72

BioMerieux's share price for today is €101.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioMerieux's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €3.010.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


BioMerieux EV-to-FCF Related Terms

Thank you for viewing the detailed overview of BioMerieux's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BioMerieux (XPAR:BIM) Business Description

Traded in Other Exchanges
Address
Marcy l’Etoile, Lyon, FRA, 69280
BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (38% of 2021 sales), microbiology (31%), immunoassays (14%), and industrial applications (about 17%). The Americas account for the largest portion of the firm's revenue (49%), followed by Europe, the Middle East, and Africa (33%), and Asia-Pacific (18%). BioMerieux is headquartered in Marcy-l'Etoile, France.

BioMerieux (XPAR:BIM) Headlines

No Headlines